Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer

Cancer Science

Volumn 107, Issue 9, 2016, Pages 1173-1178

  Kim, Soochi ^a   Kim, Boyun ^a   Song, Yong Sang ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Ascites; ovarian cancer; tumor heterogeneity

Indexed keywords

ASCITES; ASCITES TUMOR; CANCER CELL; CANCER GROWTH; CELL FUNCTION; CELL HETEROGENEITY; DISEASE COURSE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84987618880     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12987     Document Type: Review

References (77)

1. Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012; 2: 566–80.
2. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13: 273–82.
3. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945–9.
4. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011; 11: 210.
5. Lopez RI, Paul J, Atkinson R et al. Prognostic factor analysis, for patients with no evidence of disease after initial chemotherapy for advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 1996; 6: 8–14.
6. Suh DH, Kim HS, Kim B, Song YS. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. Biochem Pharmacol 2014; 92: 43–54.
7. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 2008; 22: 559–74.
8. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332–7.
9. Pasquet M, Golzio M, Mery E et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010; 126: 2090–101.
10. Matte I, Lane D, Bachvarov D, Rancourt C, Piche A. Role of malignant ascites on human mesothelial cells and their gene expression profiles. BMC Cancer 2014; 14: 288.
11. Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013; 85: 1033–41.
12. Ren J, Xiao YJ, Singh LS et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res 2006; 66: 3006–14.
13. Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K, Mizutani S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002; 63: 158–65.
14. Stadlmann S, Amberger A, Pollheimer J et al. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol 2005; 97: 784–9.
15. Latifi A, Luwor RB, Bilandzic M et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE 2012; 7: e46858.
16. Wintzell M, Hjerpe E, Avall Lundqvist E, Shoshan M. Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites. BMC Cancer 2012; 12: 359.
17. Ahmed N, Thompson EW, Quinn MA. Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007; 213: 581–8.
18. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 1994; 58: 393–9.
19. Sodek KL, Ringuette MJ, Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009; 124: 2060–70.
20. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 2009; 113: 143–8.
21. Fayad W, Brnjic S, Berglind D et al. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer 2009; 125: 2450–5.
22. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8: 878–84.
23. Ho CM, Chang SF, Hsiao CC, Chien TY, Shih DT. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J Biomed Sci 2012; 19: 23.
24. Guo L, Guo N. Exosomes: potent regulators of tumor malignancy and potential bio-tools in clinical application. Crit Rev Oncol Hematol 2015; 95: 346–58.
25. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86: 851–5.
26. Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996; 56: 83–7.
27. Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Gynecol Oncol 2002; 86: 279–87.
28. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF. Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer. Eur J Cancer 2011; 47: 1883–9.
29. Giuntoli RL 2nd, Webb TJ, Zoso A et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009; 29: 2875–84.
30. Lane D, Matte I, Garde-Granger P et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer 2015; 15: 492.
31. McMillan A, Rulisa S, Sumarah M et al. A multi-platform metabolomics approach identifies highly specific biomarkers of bacterial diversity in the vagina of pregnant and non-pregnant women. Sci Rep 2015; 5: 14174.
32. Landaas S, Jakobs C. The occurrence of 2-hydroxyisovaleric acid in patients with lactic acidosis and ketoacidosis. Clin Chim Acta 1977; 78: 489–93.
33. Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011; 19: 416–28.
34. Chung HH, Kwon HW, Kang KW et al. Preoperative F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 28–34.
35. Gwak H, Haegeman G, Tsang BK, Song YS. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Mol Carcinog 2015; 54: 1529–40.
36. Carvalho KC, Cunha IW, Rocha RM et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011; 66: 965–72.
37. Suh DH, Kim MA, Kim H et al. Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med 2014; 14: 345–53.
38. Shender VO, Pavlyukov MS, Ziganshin RH et al. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics 2014; 13: 3558–71.
39. Hartmann D, Lucks J, Fuchs S et al. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol 2012; 44: 620–8.
40. Gortzak-Uzan L, Ignatchenko A, Evangelou AI et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 2008; 7: 339–51.
41. Elschenbroich S, Ignatchenko V, Clarke B et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res 2011; 10: 2286–99.
42. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654–9.
43. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13–21.
44. So KA, Min KJ, Hong JH, Lee JK. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial–mesenchymal transition. Int J Oncol 2015; 47: 1451–9.
45. Lane D, Matte I, Rancourt C, Piche A. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res 2012; 5: 34.
46. Reid PE, Brown NJ, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer 2009; 8: 49.
47. Zhan N, Dong WG, Wang J. The clinical significance of vascular endothelial growth factor in malignant ascites. Tumour Biol 2016; 37: 3719–25.
48. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 2012; 31: 143–62.
49. Yabushita H, Shimazu M, Noguchi M et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003; 10: 89–95.
50. Yin J, Zeng F, Wu N, Kang K, Yang Z, Yang H. Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro. Clin Transl Oncol 2015; 17: 365–70.
51. Wang Y, Xu RC, Zhang XL et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012; 59: 145–55.
52. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275–91.
53. Polyak K, Marusyk A. Cancer: clonal cooperation. Nature 2014; 508: 52–3.
54. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105–17.
55. Blagden SP. Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer. Front Oncol 2015; 5: 149.
56. Auer K, Bachmayr-Heyda A, Aust S et al. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget 2015; 6: 17261–75.
57. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology 2013; 45: 229–42.
58. Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 2008; 132: 1753–60.
59. Callahan MJ, Crum CP, Medeiros F et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985–90.
60. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 2007; 211: 286–95.
61. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309–22.
62. Lane D, Robert V, Grondin R, Rancourt C, Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227–37.
63. Lane D, Goncharenko-Khaider N, Rancourt C, Piche A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010; 29: 3519–31.
64. Lane D, Matte I, Rancourt C, Piche A. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010; 3: 1.
65. Zhu FL, Ling AS, Wei Q, Ma J, Lu G. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites. Asian Pac J Cancer Prev 2015; 16: 719–22.
66. Liu F, Kong X, Dou Q et al. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Ann Hepatol 2014; 13: 357–63.
67. Kim HS, Kim JW, Chung HH, Park NH, Song YS, Kang SB. Disease confined within the ovary and smaller amount of ascites are good prognostic factors for survival of patients with squamous cell carcinoma arising from mature cystic teratoma of the ovary: a case series in Korea and review of the published reports. J Obstet Gynaecol Res 2009; 35: 99–105.
68. Chen Y, Liang B, Zhao YJ, Wang SC, Fan YB, Wu GP. Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol 2012; 40: 287–91.
69. Cheng D, Liang B, Kong H. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites. Med Oncol 2012; 29: 1397–402.
70. Wu KL, Chen HW, Lin SH, Chen JS. Intractable ascites, changes in serum vascular endothelial growth factor levels and thalidomide treatment in POEMS syndrome. Am J Med Sci 2014; 347: 510–2.
71. Zhang Y, Yu LK, Xia N. Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med 2012; 5: 239–42.
72. Wang XF, Wu YH, Wang MS, Wang YS. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev 2014; 15: 363–8.
73. Ferriss JS, Java JJ, Bookman MA et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol 2015; 139: 17–22.
74. Fossati M, Buzzonetti A, Monego G et al. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAMxanti-CD3). Gynecol Oncol 2015; 138: 343–51.
75. Markowska J, Lacki JK, Jaroszewski J, Wiktorowicz K. The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients. Eur J Gynaecol Oncol 1995; 16: 54–8.
76. Seeber A, Martowicz A, Spizzo G et al. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro. BMC Cancer 2015; 15: 372.
77. Liu C, Yang F. Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma. Tumour Biol 2015; 36: 7213–9.